Black Diamond Skiing Explained: Skills, Gear and Best Runs
Despite skiing's complicated phrases, slang, and descriptors when it comes to snow and gear, the sport uses a rather simple ...
Black Diamond Therapeutics (NASDAQ:BDTX) Receives Outperform Rating from Wedbush
Wedbush reissued their outperform rating on shares of Black Diamond Therapeutics (NASDAQ:BDTX – Free Report) in a research ...
Equities Analysts Offer Predictions for BDTX Q1 Earnings
Investment analysts at Wedbush upped their Q1 2025 EPS estimates for Black Diamond Therapeutics in a research note issued to investors on Wednesday, March 19th. Wedbush analyst R. Driscoll now expects ...
Courier-Herald on MSN4d
Black Diamond again studies fire, emergency services options
The city of Black Diamond has begun a fire protection and emergency services feasibility study in the midst of potentially ...
Black Diamond Equipment Recalls BD Vision Climbing Harnesses Due to Fall Hazard; Risk of Serious Injury and Death
This recall involves all BD Vision Harnesses. This lightweight harness is designed for technical alpine and ice climbs. All ...
Pharmaceutical Technology on MSN5d
Servier and Black Diamond sign deal for solid tumours therapy
Servier will be responsible for development and global commercialisation of the therapy for several indications.
Black Diamond Therapeutics Shares Surge on Servier Licensing Deal
Black Diamond said Servier will develop and commercialize BDTX-4933, a small molecule designed by the Cambridge, Mass., company to address unmet medical needs in RAF/RAS-mutant solid tumors.
4BDTX : Black Diamond Therapeutics Inks Licensing Pact With French Pharma...
Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an ...
Asianet Newsable on MSN6d
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High
Shares of Black Diamond Therapeutics, Inc. (BDTX) jumped around 21% as of Wednesday noon after the company announced it had ...
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with ...